|
US3227725A
(en)
|
1962-04-17 |
1966-01-04 |
Union Carbide Corp |
Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
TW201311B
(https=)
|
1991-06-17 |
1993-03-01 |
Hoffmann La Roche |
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
CA2143246C
(en)
|
1994-03-16 |
2000-08-22 |
Thierry Godel |
Imidazodiazepines
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
DE69839355T2
(de)
|
1997-07-29 |
2009-06-04 |
Alcon Laboratories, Inc., Fort Worth |
Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
|
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
DK2336167T3
(da)
|
2001-03-14 |
2019-09-02 |
Dako Denmark As |
MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi
|
|
WO2002079499A1
(en)
|
2001-04-02 |
2002-10-10 |
Wyeth |
Pd-1, a receptor for b7-4, and uses therefor
|
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
GB0204159D0
(en)
|
2002-02-22 |
2002-04-10 |
British Biotech Pharm |
Metalloproteinase inhibitors
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
EP1654002B2
(en)
|
2003-08-07 |
2014-01-29 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
TW200524601A
(en)
|
2003-12-05 |
2005-08-01 |
Bristol Myers Squibb Co |
Heterocyclic anti-migraine agents
|
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
EP1593671A1
(en)
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
|
EP1838706A1
(en)
|
2004-12-24 |
2007-10-03 |
Prosidion Limited |
G-protein coupled receptor agonists
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
EP1888512A2
(en)
|
2005-06-06 |
2008-02-20 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US20090042926A1
(en)
|
2005-12-20 |
2009-02-12 |
Jason Imbriglio |
Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
|
|
CN101484433A
(zh)
|
2006-02-15 |
2009-07-15 |
艾博特公司 |
新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
|
|
AU2007275221A1
(en)
|
2006-07-20 |
2008-01-24 |
Allen J. Borchardt |
Benzothiophene inhibitors of RHO kinase
|
|
PL2076501T3
(pl)
|
2006-09-25 |
2016-06-30 |
Ptc Therapeutics Inc |
Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
WO2009006555A2
(en)
|
2007-07-02 |
2009-01-08 |
Yu, Ming |
Methods, composition, targets for combinational cancer treatments
|
|
US7868001B2
(en)
|
2007-11-02 |
2011-01-11 |
Hutchison Medipharma Enterprises Limited |
Cytokine inhibitors
|
|
EA018551B1
(ru)
|
2008-02-22 |
2013-08-30 |
Айрм Ллк |
ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR
|
|
WO2010033701A2
(en)
|
2008-09-19 |
2010-03-25 |
Genzyme Corporation |
Inhibitors of sphingosine kinase 1
|
|
JP2012507563A
(ja)
|
2008-10-30 |
2012-03-29 |
エリクシアー ファーマシューティカルズ， インコーポレイテッド |
スルホンアミド含有化合物およびその使用
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
|
WO2011137587A1
(en)
|
2010-05-06 |
2011-11-10 |
Hutchison Medipharma Limited |
Cytokine inhibitors
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
AU2011290672B2
(en)
|
2010-08-20 |
2015-07-09 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
WO2012129564A2
(en)
|
2011-03-24 |
2012-09-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Proteasome chymotrypsin-like inhibition using pi-1833 analogs
|
|
WO2012168944A1
(en)
|
2011-06-08 |
2012-12-13 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
|
BR112014007310A2
(pt)
|
2011-09-27 |
2017-04-04 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
|
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
CA2868408A1
(en)
|
2012-03-29 |
2013-10-03 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds from the bc loop of human pd1
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9220710B2
(en)
|
2013-01-09 |
2015-12-29 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
|
JP6387360B2
(ja)
|
2013-03-14 |
2018-09-05 |
ノバルティス アーゲー |
変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
|
|
WO2014147586A1
(en)
|
2013-03-22 |
2014-09-25 |
Novartis Ag |
1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
|
|
BR112016000853A2
(pt)
|
2013-07-16 |
2017-12-12 |
Genentech Inc |
métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
|
|
AU2014309199B2
(en)
|
2013-08-20 |
2018-04-19 |
Merck Sharp & Dohme Llc |
Treating cancer with a combination of a PD-1 antagonist and dinaciclib
|
|
HUE038169T2
(hu)
|
2013-09-06 |
2018-09-28 |
Aurigene Discovery Tech Ltd |
1,2,4-Oxadiazol származékok mint immunomodulátorok
|
|
EA029661B1
(ru)
|
2013-09-06 |
2018-04-30 |
Ауриген Дискавери Текнолоджиз Лимитед |
Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
IL292510A
(en)
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
GB2516515B8
(en)
|
2013-12-04 |
2016-10-05 |
Intelligent Growth Solutions Ltd |
Automated arrangement to grow plants under lighting in a vertical tower
|
|
EP3079699A4
(en)
|
2013-12-11 |
2017-07-19 |
Glaxosmithkline LLC |
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
|
JP2016021697A
(ja)
|
2014-07-15 |
2016-02-04 |
株式会社日立製作所 |
通信システム、通信装置、及び、制御装置
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
US10174012B2
(en)
|
2014-11-04 |
2019-01-08 |
The University Of Kansas |
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
KR102894264B1
(ko)
*
|
2015-03-10 |
2025-12-02 |
오리진 온콜로지 리미티드 |
면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
|
|
BR112017019304A2
(pt)
*
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Technologies Limited |
compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
|
|
EA201791629A1
(ru)
|
2015-03-10 |
2018-02-28 |
Ауриджен Дискавери Текнолоджис Лимитед |
1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
|
|
WO2018047143A1
(en)
|
2016-09-12 |
2018-03-15 |
Aurigene Discovery Technologies Limited |
Vista signaling pathway inhibitory compounds useful as immunomodulators
|
|
WO2018051254A1
(en)
*
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
|
AU2017345500B2
(en)
|
2016-10-20 |
2022-03-10 |
Aurigene Oncology Limited |
Dual inhibitors of vista and PD-1 pathways
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
EP3694841A1
(en)
|
2017-10-11 |
2020-08-19 |
Aurigene Discovery Technologies Limited |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
|
MY206121A
(en)
|
2017-11-03 |
2024-11-29 |
Aurigene Discovery Tech Ltd |
Dual inhibitors of tim-3 and pd-1 pathways
|
|
AU2018360389B2
(en)
|
2017-11-06 |
2024-09-19 |
Aurigene Oncology Limited |
Conjoint therapies for immunomodulation
|